What is KeyCorp’s Forecast for TMO FY2025 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO) – KeyCorp issued their FY2025 earnings per share (EPS) estimates for Thermo Fisher Scientific in a research report issued on Sunday, December 7th. KeyCorp analyst P. Knight expects that the medical research company will post earnings per share of $22.77 for the year. KeyCorp currently has a “Overweight” rating and a $750.00 target price on the stock. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the prior year, the business posted $5.28 earnings per share. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS.

A number of other equities research analysts have also commented on TMO. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research report on Wednesday, October 8th. UBS Group boosted their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Finally, Barclays raised their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $612.95.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $574.19 on Wednesday. The stock has a fifty day moving average of $564.23 and a 200-day moving average of $489.10. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a market capitalization of $215.73 billion, a P/E ratio of 33.17, a price-to-earnings-growth ratio of 4.11 and a beta of 0.90.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock repurchase program on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Frederick M. Lowery sold 6,912 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total value of $4,022,369.28. Following the transaction, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,360,731.98. This represents a 32.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Lisa P. Britt sold 1,058 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the sale, the vice president directly owned 13,087 shares in the company, valued at $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 149,271 shares of company stock worth $86,507,282. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC lifted its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Covestor Ltd lifted its stake in Thermo Fisher Scientific by 22.4% in the first quarter. Covestor Ltd now owns 191 shares of the medical research company’s stock valued at $95,000 after buying an additional 35 shares during the last quarter. SouthState Corp boosted its position in shares of Thermo Fisher Scientific by 1,276.5% during the first quarter. SouthState Corp now owns 234 shares of the medical research company’s stock worth $116,000 after buying an additional 217 shares during the period. Finally, Enhancing Capital LLC bought a new position in Thermo Fisher Scientific in the 1st quarter valued at about $205,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.